BioCryst PharmaceuticalsBCRX
About: BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Employees: 531
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
96% more call options, than puts
Call options by funds: $12.6M | Put options by funds: $6.44M
51% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 35
21% more capital invested
Capital invested by funds: $1.09B [Q2] → $1.32B (+$225M) [Q3]
6% more funds holding
Funds holding: 240 [Q2] → 255 (+15) [Q3]
5% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 74
1.87% less ownership
Funds ownership: 85.61% [Q2] → 83.74% (-1.87%) [Q3]
33% less funds holding in top 10
Funds holding in top 10: 6 [Q2] → 4 (-2) [Q3]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
JMP Securities Jonathan Wolleben 43% 1-year accuracy 32 / 75 met price target | 106%upside $18 | Market Outperform Reiterated | 31 Jan 2025 |
Evercore ISI Group Liisa Bayko 67% 1-year accuracy 8 / 12 met price target | 38%upside $12 | Outperform Maintained | 13 Jan 2025 |
Needham Serge Belanger 50% 1-year accuracy 65 / 130 met price target | 72%upside $15 | Buy Maintained | 13 Jan 2025 |
Financial journalist opinion









